Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
Research ArticleFocus: Update on Myeloproliferative Neoplasms

Myeloproliferative Neoplasms: The Role of Molecular Markers

LeiLani Collins
American Society for Clinical Laboratory Science July 2011, 24 (3) 183-186; DOI: https://doi.org/10.29074/ascls.24.3.183
LeiLani Collins
University of Tennessee Health Science Center, Memphis, TN
MS, MT(ASCP)SH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lcollins@uthsc.edu
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. LeiLani Collins, MS, MT(ASCP)SH⇑
    1. University of Tennessee Health Science Center, Memphis, TN
  1. Address for Correspondence: LeiLani Collins, MS, MT(ASCP)SH, University of Tennessee Health Science Center, 930 Madison Ave., Ste. 670, Memphis, TN 38163, 901-448-6299, Fax: 901-448-7545, lcollins{at}uthsc.edu

After reading this article, the reader will be able to:

  1. Describe the fusion gene formed as a result of the translocation t(9;22)(q34;q11) in chronic myelogenous leukemia.

  2. Describe common symptoms of Philadelphia chromosome negative myeloproliferative neoplasms.

  3. State the frequency of the occurrence of the JAK2 V617F mutation in PV, ET, and PMF.

  4. Describe the significance of the JAK2 mutation in the diagnosis of PV, ET, and PMF.

  5. Describe the significance of tyrosine kinase inhibitors on the treatment of MPNs.

  6. Define current treatment for Philadelphia chromosome negative MPNs.

  7. Describe the significance of imatinib treatment for CML on treatment for the other MPNs.

Extract

The myeloproliferative neoplasms (MPN), formerly known as the myeloproliferative disorders (MPD), are a group of clonal disorders involving hyperproliferation of one or more of the myeloid cell lines (erythrocytic, granulocytic, megakaryocytic). The most common disorders traditionally classified as MPNs are chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Other, less common disorders in this group include chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), mastocytosis, and myeloproliferative neoplasm, unclassifiable (MPN,U).1 All of these neoplasms are most common in people with a median age of 65 years at diagnosis but have been diagnosed in all age groups. Common presenting signs are fatigue, splenomegaly, and elevated cell counts. Often, there are bleeding or thrombotic symptoms.

Chronic Myelogenous Leukemia (CML)—BCR/ABL1-Positive MPN CML is a disease of “firsts” that has led the way for diagnostic, treatment, and prognostic factors for the other MPNs. It is the first disorder for which the term “leukemia” was used; the first malignancy associated with a recurring chromosomal abnormality (Philadelphia chromosome); the first disease in which the chromosomal abnormality formed a fusion gene (BCR/ABL1); the first disease in which a protein fundamental to the pathogenesis of the disease was identified; and, the first disorder in which a therapeutic agent specifically targeted the molecular defect to effectively treat the disorder.1

Historically, CML was the first MPN to have a known acquired chromosomal abnormality, a reciprocal translocation between the long arms of chromosomes 9 and 22 known as the Philadelphia chromosome (Ph1) and designated as…

After reading this article, the reader will be able to:

  1. Describe the fusion gene formed as a result of the translocation t(9;22)(q34;q11) in chronic myelogenous leukemia.

  2. Describe common symptoms of Philadelphia chromosome negative myeloproliferative neoplasms.

  3. State the frequency of the occurrence of the JAK2 V617F mutation in PV, ET, and PMF.

  4. Describe the significance of the JAK2 mutation in the diagnosis of PV, ET, and PMF.

  5. Describe the significance of tyrosine kinase inhibitors on the treatment of MPNs.

  6. Define current treatment for Philadelphia chromosome negative MPNs.

  7. Describe the significance of imatinib treatment for CML on treatment for the other MPNs.

  • © Copyright 2011 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 24 (3)
American Society for Clinical Laboratory Science
Vol. 24, Issue 3
Summer 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Myeloproliferative Neoplasms: The Role of Molecular Markers
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Myeloproliferative Neoplasms: The Role of Molecular Markers
LeiLani Collins
American Society for Clinical Laboratory Science Jul 2011, 24 (3) 183-186; DOI: 10.29074/ascls.24.3.183

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Myeloproliferative Neoplasms: The Role of Molecular Markers
LeiLani Collins
American Society for Clinical Laboratory Science Jul 2011, 24 (3) 183-186; DOI: 10.29074/ascls.24.3.183
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Essential Thrombocythemia
  • Myeloproliferative Neoplasms: An Overview
Show more Focus: Update on Myeloproliferative Neoplasms

Similar Articles

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire